Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Assembly Biosciences's Net Margin % or its related term are showing as below:
FRA:V7B'
s Net Margin % Range Over the Past 10 Years
Min: -2076.35 Med: -543.14 Max: -8.47
Current: -8.98
FRA:V7B's Net Margin % is ranked better than 66.88% of 942
companies
in the Biotechnology industry
Industry Median: -89.445
vs FRA:V7B: -8.98
Assembly Biosciences (FRA:V7B) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Assembly Biosciences Net Margin % Related Terms
Assembly Biosciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:V7B vs CTNM, PRTA, RGNX: Net Margin % Comparison
For the Biotechnology subindustry, Assembly Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences (FRA:V7B) has a Net Margin % of -110.54% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Assembly Biosciences and its competitors. According to the industry distribution chart, Assembly Biosciences ranks #312 out of 942 companies in the Biotechnology industry, placing it in the top 33.1%.
Is Assembly Biosciences' Net Margin % too high?
Assembly Biosciences' current Net Margin % is -110.54%. Based on the distribution chart, Assembly Biosciences ranks #312 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Assembly Biosciences has a GF Score™ of 37/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Net Margin % compare to CTNM and PRTA?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #312 out of 942 companies for Net Margin %. This puts Assembly Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current Net Margin % is -110.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Assembly Biosciences (FRA:V7B) is currently considered Modestly Overvalued. The stock's GF Value™ is €17.56, compared to a current price of €21.85 — trading 24.4% above its estimated fair value. The current Net Margin % is -110.54%. Assembly Biosciences' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Assembly Biosciences (FRA:V7B), the current Net Margin % is -110.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Assembly Biosciences (FRA:V7B) Overvalued in 2026?
Based on GuruFocus' analysis, Assembly Biosciences stock appears to be overvalued.
The current stock price of €21.85 is trading 24.4% above its estimated GF Value™ of €17.56.
GuruFocus considers Assembly Biosciences to be Modestly Overvalued.
Key valuation signals for FRA:V7B:
Net Margin %: -110.54%
GF Value™: €17.56 vs. price of €21.85 (24.4% above fair value)
No single metric tells the full story. See the FRA:V7B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
37GF Score
Get the complete analysis for FRA:V7B
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:V7B has been successfully added to your 
